Targeting TBK1 to overcome resistance to cancer immunotherapy

2023

Author

Sun Y, Revach OY, Anderson S, Kessler EA, Wolfe CH, Jenney A, Mills CE, Robitschek EJ, Davis TGR, Kim S, Fu A, Ma X, Gwee J, Tiwari P, Du PP, Sindurakar P, Tian J, Mehta A, Schneider AM, Yizhak K, Sade-Feldman M, LaSalle T, Sharova T, Xie H, Liu S, Michaud WA, Saad-Beretta R, Yates KB, Iracheta-Vellve A, Spetz JKE, Qin X, Sarosiek KA, Zhang G, Kim JW, Su MY, Cicerchia AM, Rasmussen MQ, Klempner SJ, Juric D, Pai SI, Miller DM, Giobbie-Hurder A, Chen JH, Pelka K, Frederick DT, Stinson S, Ivanova E, Aref AR, Paweletz CP, Barbie DA, Sen DR, Fisher DE, Corcoran RB, Hacohen N, Sorger PK, Flaherty KT, Boland GM, Manguso RT, Jenkins RW

Published

January 11, 2023

Doi

10.1038/s41586-023-05704-6

Abstract

We demonstrate that targeting TBK1 is a novel and effective strategy to overcome resistance to cancer immunotherapy.

Publication Metrics

Journal

Nature

Details

Published 12 January, 2023

Citation

Sun, Yi, Or-yam Revach, Seth Anderson, Emily A. Kessler, Clara H. Wolfe, Anne Jenney, Caitlin E. Mills, et al. 2023. "Targeting TBK1 to Overcome Resistance to Cancer Immunotherapy." Nature, January. https://doi.org/10.1038/s41586-023-05704-6.